What is known is that high-risk MM subtypes (i.e., MF, PR, MS) [114] express NIMA (never in mitosis gene A)-related kinase 2 (NEK2), have low-PDL1 levels, and are less likely to respond to anti-PD1 therapy. Here, NEK2 is linked to Miyoshi myopathy.